Insulet To Present Omnipod Clinical Studies On Type 1 And Type 2 Diabetes During The American Diabetes Association’s 76th Scientific Sessions

Company Presentations Include Compelling Clinical Data Demonstrating the Efficacy of the Omnipod System on Glycemic Control in Patients with Type 1 and Type 2 Diabetes

Dr. Frank Doyle to Share Exciting New Data on the Insulet-Licensed Artificial Pancreas Algorithm

Company Exhibiting at Booth 1301; Available to Review Details on Clinical Outcomes and Recently Launched Patient Mobile App and Omnipod Podder^TM Community Platform

BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod^® Insulin Management System (Omnipod System), today announced new clinical data for the Company’s Omnipod System will be presented at the American Diabetes Association (ADA) 76^th Scientific Sessions in New Orleans, La., June 10-14, 2016. Insulet expects that the studies will begin to form a body of clinical evidence to support the unique benefits of the Omnipod System. The studies include large, retrospective analyses of patients with type 1 and type 2 diabetes. Data on Insulet’s recently licensed artificial pancreas algorithm will also be highlighted at the conference.

“We are pleased to present several new studies on the benefits of our Omnipod System in type 1 and type 2 diabetes patients for whom effective treatments are important given the enormous daily burden associated with managing their disease”

“We are pleased to present several new studies on the benefits of our Omnipod System in type 1 and type 2 diabetes patients for whom effective treatments are important given the enormous daily burden associated with managing their disease,” said Patrick Sullivan, President and Chief Executive Officer. “We are deeply committed to improving the lives of people with diabetes by offering advanced education and resources to our growing Podder community. We also remain focused on innovation through our Digital Insulet strategy, which will increase patient mobile connectivity and ultimately help deliver our first product with artificial pancreas functionality.”

* Data subject to embargo until Saturday, June 11, 2016
** CSII – Continuous Subcutaneous Insulin Infusion; MDI – Multiple Daily Injections

Future Pipeline:

Insulet continues to make progress incorporating artificial pancreas technology into future generations of the Omnipod System. The Company’s first artificial pancreas system will rely on the unique Omnipod platform coupled with the latest DexCom CGM technology and will be powered by the algorithm licensed from Mode AGC in February 2016. Frank Doyle, PhD, Dean of the Harvard John A. Paulson School of Engineering and Applied Sciences, and Eyal Dassau, PhD, senior research fellow in Biomedical Engineering in the Harvard John A. Paulson School of Engineering and Applied Sciences, will present exciting new data on the clinical benefits of this algorithm in the “Closing the Loop” session from 8 a.m. to 10 a.m. (CT) on Saturday, June 11, 2016 in La Nouvelle Orleans AB in the Moriel Convention Center. A feasibility study involving the algorithm and a next-generation Omnipod prototype is underway and the Company expects to begin on-body trials later this year.

Insulet’s Commitment to Podder Community to be Showcased During the ADA Meeting:

Insulet will also exhibit at this year’s Scientific Sessions at Booth Location 1301. The exhibit will prominently feature the recently launched Omnipod re-branding and several new patient support resources, including:

• The Podder Community platform, providing support, information and a social engagement forum for the Omnipod patient community, notably a new presence on Facebook (myomnipod) and Twitter (@myomnipod).
• Initial release of the Omnipod patient mobile app, featuring educational content and product reorder capabilities.

About the Omnipod Insulin Management System:

The Omnipod Insulin Management System is an innovative continuous insulin delivery system that provides all the proven benefits of continuous subcutaneous insulin infusion (CSII) therapy in a way no conventional insulin pump can. The Omnipod System’s innovative design and features allows people living with diabetes to live their life—and manage their diabetes—with unprecedented freedom, comfort, convenience, and ease. The Omnipod System consists of two components: (i) a Pod that stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM) that wirelessly programs the user’s personalized insulin delivery, calculates suggested doses and insulin on board, and has a convenient, built-in blood glucose meter. The small, light-weight Pod can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back and, because it is waterproof (IPX8), there is no need to remove when showering, swimming or performing other activities. This means that Omnipod can provide up to three days of non-stop insulin delivery, without the need to disconnect a tube set or manually inject insulin. The Pod and PDM communicate wirelessly to offer precise, personalized and continuous insulin delivery with customizable basal and bolus delivery options, as well as important safety checks. The Pod’s auto-cannula insertion is quick, simple, and virtually pain-free. Users never have to handle a needle. The user simply pushes a button on the PDM and the Pod’s automated insertion system inserts the cannula beneath the skin and begins delivering insulin according to the user’s programmed basal rate.

The Omnipod System is the world’s first commercially available tubeless insulin delivery system that allows users to live untethered by tubing and without the stress and anxiety of multiple daily injections. By breaking down the barriers to insulin pump therapy, the Omnipod System offers freedom for users to live life on their own terms and with the ease of use they deserve.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet’s Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. To read inspiring stories of people with diabetes living their lives to the fullest with Omnipod, please visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet’s expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 29, 2016 in the section entitled “Risk Factors,” and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.